Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
These 10 Stocks Were S&P 500's Top Performers In Biden's First Year: Could The Trend Continue If Harris Wins 2024 Election?
A look at the top 10 performing S&P 500 stocks in 2021 could point to trends to watch if Kamala Harris wins the 2024 election. 
Via Benzinga
Topics Stocks
Exposures US Equities
Behind the Scenes of Moderna's Latest Options Trends
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 27
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Moderna Unusual Options Activity For October 22
Via Benzinga
A Closer Look at Moderna's Options Market Dynamics
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today
Via Benzinga
How Bad Is This News for Novavax?
Novavax stock fell 20% in one trading session on the news. 
Via The Motley Fool
Large-Cap Stocks In Trouble - Saturday, Oct. 19
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Benzinga Bulls And Bears: Apple, Tesla, Netflix, Oklo — And Dogecoin, Meme Coins Outpace Corporate Giants
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season
Goldman Sachs identified 20 stocks with high short interest that could be primed for a short squeeze. Hint: A pet retailer tops the chart. 
Via Benzinga
Unveiling 18 Analyst Insights On Moderna
Via Benzinga
(MRNA) - Analyzing Moderna's Short Interest
Via Benzinga
Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
S. markets ended Thursday with mixed performance: the Dow Jones Industrial Average climbed 0.4% to 43,239.05. 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
On Wednesday, Cathie Wood’s Ark Invest made significant trades involving Block Inc (NYSE:SQ) and Moderna Inc (NASDAQ:MRNA). The SQ Trade 
Via Benzinga
Cathie Wood's Ark Offloads $1.28M In Jack Dorsey's Block Shares Despite Bitcoin Rally
On Tuesday, Cathie Wood-led Ark Invest made significant trades, most notably selling off shares of Block Inc. (NYSE:SQ). The SQ Trade 
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
The Bull's Biggest Hits And Misses
The bull market turned two years old over the weekend. Here are some of the S&P 500's biggest winners and losers over the last two years. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
2 Biotech Stocks That Are Screaming Buys This Month
They won't remain southbound forever. 
Via The Motley Fool
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
On Thursday Oct 10, 2024 Cathie Wood-Led Ark Invest sold over $9 million worth of Moderna stock. 
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
Could rebounds be in store for these beaten-down stocks? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.